10-Q: Scilex Holding Company Reports Q2 2024 Results: Revenue Growth Offset by Increased Losses

Scilex Holding Company's Q2 2024 results show revenue growth driven by ZTlido and ELYXYB, but increased operating expenses and losses.

Summary

• Scilex Holding Company reported a net revenue of $16.4 million for the three months ended June 30, 2024, compared to $12.6 million for the same period in 2023.
• The increase in revenue was primarily driven by higher sales of ZTlido and ELYXYB, and the launch of GLOPERBA in June 2024.
• Operating costs and expenses totaled $32 million for the quarter, compared to $35.4 million in the prior year.
• The company experienced a loss from operations of $15.6 million, compared to a loss of $22.8 million in the same quarter of 2023.
• The net loss for the quarter was $37.6 million, or $0.31 per share, compared to a net loss of $26.6 million, or $0.19 per share, in the prior year.
• For the six months ended June 30, 2024, net revenue was $27.3 million, compared to $23.2 million in 2023.
• The net loss for the six months ended June 30, 2024 was $62 million, or $0.56 per share, compared to a net loss of $57.4 million, or $0.40 per share, in the prior year.
• The company's negative working capital was $205 million as of June 30, 2024, including cash and cash equivalents of approximately $6.9 million.
• Scilex had an accumulated deficit of $552.2 million as of June 30, 2024.
• The company has plans to obtain additional resources to fund its operations and service its debt obligations through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with positive revenue growth but significant losses and going concern issues. The need for additional funding and the risks associated with the company's operations and debt obligations contribute to a negative sentiment.

Positives

• Net revenue increased by $3.8 million in Q2 2024 compared to Q2 2023.
• The company's operating loss improved by $7.2 million in Q2 2024 compared to Q2 2023.
• Scilex launched GLOPERBA in June 2024.
• The company received a $10 million non-refundable deposit from FSF Lender in June 2024.
• The company made mandatory prepayments of $9.6 million and $7 million to Oramed following the Registered Direct Offering and the receipt of the FSF Deposit, respectively.

Negatives

• The net loss increased to $37.6 million in Q2 2024, compared to $26.6 million in Q2 2023.
• The company's negative working capital was $205 million as of June 30, 2024.
• Scilex had an accumulated deficit of $552.2 million as of June 30, 2024.
• The company's management has concluded that there is substantial doubt about its ability to continue as a going concern for one year after the date that the unaudited condensed consolidated financial statements are issued.

Risks

• The company is heavily dependent on the commercial success of ZTlido, as ELYXYB and GLOPERBA are in the initial stages of commercialization.
• Scilex relies on sole or single-source suppliers and manufacturers for its products and product candidates.
• The company may not be able to obtain regulatory approval for its product candidates.
• Scilex has a limited operating history and has incurred significant losses since its inception.
• The terms of the Oramed Note place restrictions on the company's operating and financial flexibility.
• The company will require substantial additional funding, which may not be available on acceptable terms, or at all.
• The market price of the company's Common Stock may fluctuate significantly.
• The company's Executive Chairman may have actual or potential conflicts of interest because of his position with Sorrento.

Future Outlook

The company expects to continue to make investments in its sales and marketing organization and expand digital marketing efforts to broaden awareness of ZTlido, GLOPERBA and ELYXYB and in research and development, clinical trials and regulatory affairs to develop its product candidates. The company will need substantial additional funding to support its continuing operations and pursue its growth strategy.

Management Comments

• Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for one year after the date that the unaudited condensed consolidated financial statements are issued.
• The company has plans to obtain additional resources to fund its operations and service its debt obligations through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions.

Industry Context

The company operates in the competitive pharmaceutical and biotechnology industries, focusing on non-opioid pain management products. The company's performance is influenced by market acceptance of its products, competition from other companies, and regulatory approvals.

Comparison to Industry Standards

• Scilex's revenue growth is positive, but its losses are significant, which is not uncommon for companies in the early stages of commercialization in the biotechnology sector.
• Compared to established pharmaceutical companies, Scilex's revenue is relatively low, and its reliance on a limited number of products and suppliers poses a higher risk.
• The company's negative working capital and accumulated deficit are concerning and highlight the need for additional funding.
• The company's reliance on debt financing, such as the Oramed Note, is a common strategy for early-stage companies, but it also increases financial risk.
• The company's clinical trial progress for SEMDEXA, SP-103 and SP-104 is consistent with other companies in the development stage, but the outcomes of these trials are uncertain.

Legal Proceedings

• The company is involved in ongoing litigation related to ZTlido patents.
• The company entered into a settlement agreement with Takeda to resolve the GLOPERBA patent litigation.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings and potential loss of investment due to the company's financial condition.
• Employees may be affected by potential cost-cutting measures or changes in the company's operations.
• Customers may experience disruptions in the supply of products if the company faces manufacturing or distribution issues.
• Suppliers and creditors face the risk of non-payment if the company's financial condition deteriorates.

Next Steps

• The company will continue to make investments in its sales and marketing organization and expand digital marketing efforts to broaden awareness of ZTlido, GLOPERBA and ELYXYB.
• The company will continue to invest in research and development, clinical trials and regulatory affairs to develop its product candidates, SEMDEXA, SP-103 and SP-104.
• The company will seek additional financing to fund its current operations, including the commercialization of ZTlido, GLOPERBA and ELYXYB, as well as the development of its other material product candidates for the next 12 months.
• The company will continue to explore and evaluate additional opportunities to grow its business.

Key Dates

Keywords

ZTlido, ELYXYB, GLOPERBA, SEMDEXA, SP-103, SP-104, revenue, net loss, clinical trials, FDA approval, debt, financing, pharmaceutical, biotechnology